Calciumfolinate Teva: Uses, Dosage & Side Effects
A prescription injectable form of folinic acid used as rescue therapy after high-dose methotrexate and as an enhancer of 5-fluorouracil chemotherapy
Calciumfolinate Teva contains the active substance folinic acid (calcium folinate, also known as leucovorin), a reduced and biologically active form of folic acid. It is a prescription-only injectable medication primarily used in two clinical settings: as a rescue agent to counteract the toxic effects of high-dose methotrexate chemotherapy, and in combination with 5-fluorouracil (5-FU) to enhance its anticancer activity in the treatment of colorectal and other cancers. Calcium folinate is on the WHO Model List of Essential Medicines and is administered exclusively in hospital settings under the supervision of specialist physicians experienced in cancer chemotherapy.
Quick Facts: Calciumfolinate Teva
Key Takeaways
- Calcium folinate (leucovorin) is a biologically active, reduced form of folic acid that bypasses the enzymatic block caused by methotrexate, making it essential as a rescue therapy after high-dose methotrexate chemotherapy to protect normal tissues.
- When combined with 5-fluorouracil (5-FU), calcium folinate enhances the anticancer effect by stabilizing the binding of 5-FU to thymidylate synthase, a strategy widely used in colorectal cancer treatment regimens such as FOLFOX and FOLFIRI.
- This medication is administered exclusively in hospital settings via intravenous infusion or intramuscular injection, under the supervision of a physician experienced in cancer chemotherapy.
- Calcium folinate must not be used to treat megaloblastic anemia caused by vitamin B12 deficiency (pernicious anemia), as it may mask the underlying condition while allowing neurological damage to progress.
- When given alongside 5-fluorouracil, the gastrointestinal and hematological toxicities of 5-FU are significantly increased, requiring careful monitoring of blood counts, hydration, and electrolyte balance.
What Is Calciumfolinate Teva and What Is It Used For?
Calciumfolinate Teva contains the active substance folinic acid in the form of its calcium salt (calcium folinate, also known internationally as leucovorin calcium). Folinic acid is the 5-formyl derivative of tetrahydrofolic acid, a naturally occurring reduced form of folic acid that plays an essential role in many critical biochemical processes in the body, including DNA synthesis, amino acid metabolism, and cell division. Unlike standard folic acid, folinic acid does not require enzymatic reduction by dihydrofolate reductase (DHFR) to become biologically active, which is the fundamental property that makes it invaluable in clinical oncology.
The medication is supplied as a clear, yellowish solution for injection at a concentration of 10 mg/ml, available in vial sizes of 5 ml, 10 ml, 20 ml, 30 ml, and 50 ml. It can be administered by intravenous injection, intravenous infusion, or intramuscular injection, depending on the clinical indication and treatment protocol. All administration is carried out in hospital settings by qualified healthcare professionals.
Calcium folinate has been included on the WHO Model List of Essential Medicines since its earliest editions, reflecting its critical importance in cancer treatment worldwide. It is recognized as an indispensable component of many standard chemotherapy regimens and is used in healthcare facilities across the globe.
Leucovorin Rescue After High-Dose Methotrexate
The primary and most well-known use of calcium folinate is as a rescue agent following treatment with high-dose methotrexate, a potent anticancer drug classified as a folate antagonist. Methotrexate works by inhibiting dihydrofolate reductase (DHFR), the enzyme responsible for converting folic acid into its active tetrahydrofolate form. While this mechanism effectively kills rapidly dividing cancer cells, it also affects normal healthy cells, particularly those in the bone marrow, gastrointestinal lining, and mucous membranes.
In leucovorin rescue therapy, calcium folinate is administered at carefully timed intervals after the methotrexate infusion. Because folinic acid is already in a reduced, active form, it can supply the tetrahydrofolate that normal cells need for DNA synthesis without requiring DHFR. This effectively bypasses the methotrexate block in healthy tissues while maintaining the anticancer effect of methotrexate against tumor cells. The timing, dose, and duration of leucovorin rescue are critical and are determined by the oncologist based on the methotrexate dose administered and the patient's serum methotrexate levels.
Combination with 5-Fluorouracil in Cancer Treatment
The second major indication for calcium folinate is its use in combination with 5-fluorouracil (5-FU) in the treatment of advanced colorectal cancer and other solid tumors. In this application, calcium folinate does not serve a protective role but instead enhances the anticancer activity of 5-FU through a biochemical mechanism known as ternary complex stabilization.
5-Fluorouracil exerts its anticancer effect in part by inhibiting the enzyme thymidylate synthase, which is essential for DNA synthesis. The active metabolite of 5-FU (5-FdUMP) binds to thymidylate synthase and forms a ternary complex with the folate cofactor 5,10-methylenetetrahydrofolate. Calcium folinate increases the intracellular pool of this folate cofactor, thereby stabilizing and prolonging the inhibition of thymidylate synthase. This results in a greater and more sustained anticancer effect. Major chemotherapy regimens that employ this combination include FOLFOX (5-FU, leucovorin, and oxaliplatin), FOLFIRI (5-FU, leucovorin, and irinotecan), and FOLFOXIRI (5-FU, leucovorin, oxaliplatin, and irinotecan), which form the backbone of colorectal cancer treatment globally.
Clinical trials and systematic reviews, including large meta-analyses published in the Journal of Clinical Oncology and the Cochrane Database of Systematic Reviews, have consistently demonstrated that the addition of leucovorin to 5-FU significantly improves response rates in advanced colorectal cancer compared to 5-FU alone. The European Society for Medical Oncology (ESMO), the National Comprehensive Cancer Network (NCCN), and other major oncological guidelines recommend leucovorin-modulated 5-FU as a standard component of first-line treatment for metastatic colorectal cancer.
What Should You Know Before Using Calciumfolinate Teva?
Contraindications
There are specific medical situations in which Calciumfolinate Teva must not be used. Understanding these contraindications is critical for patient safety. You should not receive calcium folinate if you have a known allergy (hypersensitivity) to calcium folinate or to any of the other ingredients in the formulation, including sodium chloride, sodium hydroxide, hydrochloric acid, and water for injections.
Importantly, calcium folinate must not be used to treat anemia caused by vitamin B12 deficiency, also known as pernicious anemia or other megaloblastic anemias where vitamin B12 is deficient. Although calcium folinate can temporarily improve the hematological markers (blood counts) in B12-deficient anemia, it does not address the underlying B12 deficiency and may actually mask the diagnosis. This is particularly dangerous because vitamin B12 deficiency causes progressive and potentially irreversible neurological damage (subacute combined degeneration of the spinal cord), which will continue undetected if the anemia is superficially corrected by folinate administration. For the same reason, folic acid supplements should not be given to treat B12-deficient megaloblastic anemia, and this principle applies equally to folinic acid.
Warnings and Precautions
When calcium folinate is used in combination with 5-fluorouracil, the toxicity profile of 5-FU is significantly enhanced. Elderly patients and those with impaired organ function are at particularly high risk. Fatal outcomes from severe gastrointestinal toxicity and bone marrow suppression have been reported. Close monitoring of blood counts and clinical status is mandatory.
Before receiving Calciumfolinate Teva, inform your doctor about your complete medical history. Special precautions are required in the following situations:
- Epilepsy: Calcium folinate may reduce the effectiveness of antiepileptic medications, including phenobarbital, phenytoin, primidone, and succinimides. This can increase the frequency of seizures in patients with epilepsy. If you have epilepsy and are receiving calcium folinate therapy, your doctor may need to adjust your antiepileptic medication doses and monitor you more closely.
- Combination with 5-fluorouracil: When calcium folinate is given together with 5-FU, the gastrointestinal toxicity of 5-FU is substantially increased. Diarrhea is the most common dose-limiting toxicity and can be severe, leading to dangerous dehydration and electrolyte imbalances. Mucositis (inflammation of the mucous membranes in the mouth and gastrointestinal tract) can become life-threatening. Your healthcare team will monitor you closely for these side effects and may adjust or interrupt treatment as needed.
- Kidney impairment: If you have reduced kidney function and are receiving calcium folinate as part of leucovorin rescue after high-dose methotrexate, your doctor will be especially vigilant. Impaired renal function can delay the clearance of methotrexate, potentially requiring higher doses or a longer duration of leucovorin rescue to prevent life-threatening methotrexate toxicity.
- Elderly patients: Older adults are at increased risk of severe toxicity when receiving calcium folinate in combination with 5-FU. Age-related decline in organ function, particularly kidney and liver function, may necessitate dose reductions and more frequent monitoring.
Pregnancy and Breastfeeding
There are no known risks associated with calcium folinate itself during pregnancy. Folinic acid is a naturally occurring vitamin derivative, and calcium folinate has not been associated with teratogenic effects in preclinical studies. However, it is essential to recognize that calcium folinate is almost always administered in the context of cancer chemotherapy regimens that include highly toxic drugs such as methotrexate and 5-fluorouracil, both of which are contraindicated during pregnancy due to their known teratogenic and embryotoxic effects.
If you are pregnant, think you may be pregnant, or are planning to become pregnant, you should discuss this with your oncologist before starting any chemotherapy regimen that includes calcium folinate. In the rare situation where calcium folinate is used alone (outside of chemotherapy), it may be used during pregnancy when considered necessary by the treating physician.
It is not known whether calcium folinate passes into breast milk. Given that the medication is predominantly used alongside chemotherapy agents that are excreted in breast milk and can harm a nursing infant, breastfeeding is generally not recommended during and for a period after combination chemotherapy. Your doctor will advise you on the appropriate timing for resuming breastfeeding.
Driving and Operating Machinery
Calcium folinate itself is not known to impair the ability to drive or operate machinery. However, patients receiving calcium folinate are typically undergoing chemotherapy, which can cause fatigue, nausea, and other symptoms that may affect alertness and coordination. You should assess your own fitness to drive based on your overall condition during treatment and follow your healthcare team's advice.
Sodium Content
Calciumfolinate Teva contains sodium as an excipient. The sodium content varies by vial size: approximately 16 mg per 5 ml vial, 32 mg per 10 ml vial, 63 mg per 20 ml vial, 95 mg per 30 ml vial, and 157 mg per 50 ml vial. The largest vial (50 ml) contains approximately 8% of the WHO recommended maximum daily intake of 2 g sodium for an adult. This should be taken into account for patients on a sodium-restricted diet, particularly when multiple vials are administered.
How Does Calciumfolinate Teva Interact with Other Drugs?
Calcium folinate has several clinically important drug interactions that your healthcare team will manage carefully. Because this medication is administered in a hospital setting, your oncologist and pharmacist will be responsible for assessing potential interactions and adjusting your treatment accordingly. However, it is important to inform your doctor about all medications you are currently taking, including over-the-counter drugs, herbal supplements, and vitamins.
Major Interactions
| Interacting Drug | Effect | Clinical Advice |
|---|---|---|
| 5-Fluorouracil (5-FU) | Calcium folinate enhances both the therapeutic effect and the toxicity of 5-FU by stabilizing the ternary complex of 5-FdUMP with thymidylate synthase | Intentional combination in cancer treatment. Close monitoring of gastrointestinal toxicity and blood counts is mandatory. Dose adjustments may be required based on toxicity. |
| Methotrexate | Calcium folinate counteracts the toxic effects of methotrexate by providing reduced folate that bypasses the DHFR block. At very high folinate doses, it may also reduce methotrexate's anticancer efficacy. | Used intentionally as leucovorin rescue. Timing and dosing are critical. Serum methotrexate levels guide rescue duration and intensity. |
| Trimethoprim / Sulfamethoxazole (Co-trimoxazole) | Calcium folinate may reduce or abolish the antibacterial effect of these folate antagonist antibiotics by providing an alternative folate source to bacteria | Avoid concurrent use if possible. If co-administration is necessary, monitor clinical response to the antibiotic closely. |
| Pyrimethamine | Calcium folinate may reduce or abolish the antimalarial and antiprotozoal efficacy of pyrimethamine, which acts as a folate antagonist | Avoid concurrent use when pyrimethamine is being used therapeutically. If both are needed, alternative antimalarial agents should be considered. |
Minor Interactions
| Interacting Drug | Effect | Clinical Advice |
|---|---|---|
| Phenobarbital | Calcium folinate may reduce the plasma concentration and therapeutic effect of phenobarbital, increasing seizure risk in epileptic patients | Monitor phenobarbital levels and seizure control. Dose adjustment may be necessary during and after folinate therapy. |
| Phenytoin | Calcium folinate may increase the metabolism of phenytoin, reducing its serum concentration and antiepileptic efficacy | Monitor phenytoin levels and clinical seizure control. Consider dose adjustment of phenytoin if needed. |
| Primidone and Succinimides | Similar mechanism to phenobarbital — calcium folinate may reduce the effectiveness of these antiepileptic drugs | Close monitoring of seizure frequency is recommended. Inform your neurologist that you are receiving calcium folinate. |
Calcium folinate injection must not be mixed in the same infusion solution or syringe with certain other drugs due to physical or chemical incompatibility. Known incompatibilities include droperidol, 5-fluorouracil (direct mixing causes precipitation), foscarnet, and methotrexate. When multiple drugs are administered intravenously, the line must be flushed between each drug to prevent precipitation. Your healthcare team will manage all pharmaceutical preparation and administration.
What Is the Correct Dosage of Calciumfolinate Teva?
Calciumfolinate Teva dosing is highly individualized and varies widely depending on the specific clinical indication. Unlike medications taken at home with fixed doses, calcium folinate dosing in oncology is calculated and administered by specialist physicians and pharmacists in a hospital setting. The following information provides general guidance on the dosing principles used in clinical practice.
Leucovorin Rescue After High-Dose Methotrexate
Standard Leucovorin Rescue Protocol
Starting dose: Typically 15 mg (approximately 10 mg/m²) given as the first dose 12-24 hours after the start of methotrexate infusion
Frequency: Every 6 hours for a minimum of 60 hours (10 doses) or until serum methotrexate levels fall below 0.05 micromol/L
Route: Intravenous injection, intravenous infusion, or intramuscular injection
Dose adjustments: If methotrexate elimination is delayed (due to renal impairment, third-space fluid accumulation, or other factors), higher doses and a longer duration of leucovorin rescue may be required, sometimes up to 100-200 mg/m² per dose
Monitoring: Serum methotrexate levels, serum creatinine, urinary pH, and complete blood counts are measured regularly to guide rescue therapy
The adequacy of leucovorin rescue is assessed by monitoring serum methotrexate concentrations at 24, 48, and 72 hours after methotrexate administration. If methotrexate levels remain elevated (indicating delayed clearance), the leucovorin dose is increased and the rescue period is extended. Delayed methotrexate elimination is more likely in patients with renal impairment, ascites, pleural effusions, or those who are dehydrated. Adequate hydration and urinary alkalinization are essential adjuncts to leucovorin rescue.
Combination with 5-Fluorouracil
5-FU Combination Regimens
Common regimens: Calcium folinate is used in various established chemotherapy protocols, including the de Gramont regimen, simplified FOLFOX, and FOLFIRI
Typical leucovorin dose: 200-400 mg/m² administered as a 2-hour intravenous infusion, followed by 5-FU bolus and/or continuous infusion
Frequency: Repeated every 2 weeks (biweekly cycles) in most modern regimens
Duration of treatment: Determined by the oncologist based on treatment response, disease progression, and tolerability. Treatment courses typically range from 12 to 24 cycles.
The specific dose and administration schedule of calcium folinate within 5-FU combination regimens vary according to the protocol being followed. In the widely used FOLFOX regimen for colorectal cancer, calcium folinate 400 mg/m² is typically given as a 2-hour intravenous infusion concurrently with oxaliplatin, followed by 5-FU bolus injection and then a 46-hour continuous 5-FU infusion. The exact protocol may vary between cancer centers, and your oncologist will determine the most appropriate regimen for your specific situation.
Administration Guidelines
Calciumfolinate Teva can be administered by intravenous injection, intravenous infusion (after dilution with 0.9% sodium chloride solution or 5% glucose solution), or intramuscular injection. The following important administration guidelines apply:
- Maximum injection rate: When given by intravenous injection, the rate should not exceed 160 mg of calcium folinate per minute due to the calcium content of the solution.
- Visual inspection: Before administration, the solution must be visually inspected. It should be clear and yellowish. If the solution appears cloudy, discolored, or contains particles, it must not be used and should be disposed of according to local pharmaceutical waste regulations.
- Single use: The product is intended for single use only. Any unused solution must be discarded after opening.
- Diluted solution stability: After dilution, the solution maintains chemical and physical stability for up to 72 hours at room temperature (not exceeding 25 degrees Celsius). However, from a microbiological standpoint, the diluted product should be used immediately unless prepared under validated aseptic conditions.
Missed Dose
Because Calciumfolinate Teva is administered by healthcare professionals in a hospital setting, the risk of missed doses is minimal. However, in the context of leucovorin rescue after methotrexate, timing is critical. If a dose is inadvertently delayed or missed, your healthcare team will take immediate steps to administer the dose and may adjust subsequent doses to ensure adequate rescue. Delayed or inadequate leucovorin rescue can result in severe and potentially life-threatening methotrexate toxicity.
Overdose
There are no specific reports of serious adverse effects from calcium folinate overdose when given alone. However, excessive doses of calcium folinate administered concurrently with 5-fluorouracil can lead to enhanced 5-FU toxicity. In the setting of leucovorin rescue after methotrexate, excessively high doses of calcium folinate may theoretically reduce the anticancer efficacy of methotrexate by over-rescuing both normal and tumor cells. Your oncologist carefully calculates the dose to balance rescue efficacy against this risk.
What Are the Side Effects of Calciumfolinate Teva?
Like all medications, Calciumfolinate Teva can cause side effects, although not everybody experiences them. The side effect profile differs significantly depending on whether calcium folinate is used alone or in combination with other chemotherapy agents, particularly 5-fluorouracil.
Side Effects of Calcium Folinate Alone
When calcium folinate is administered on its own (for example, as part of leucovorin rescue without concurrent 5-FU), side effects are generally uncommon and mild:
Uncommon
Affects fewer than 1 in 100 patients
- Fever
Rare
Affects fewer than 1 in 1,000 patients
- Sleep disturbances (insomnia)
- Agitation or restlessness (after high doses)
- Depression (after high doses)
- Increased seizure frequency in patients with epilepsy
- Gastrointestinal disturbances (after high doses)
Very Rare
Affects fewer than 1 in 10,000 patients
- Allergic reactions (anaphylactoid/anaphylactic reactions) — may include swelling of the lips, tongue or throat, difficulty breathing, dizziness, sudden skin rash, and itching. Seek immediate medical attention.
Side Effects When Combined with 5-Fluorouracil
When calcium folinate is administered together with 5-fluorouracil, the toxicity profile of 5-FU is significantly enhanced. This is an expected pharmacological consequence of the combination and is managed by the oncology team through dose adjustments, supportive care, and careful monitoring. The following side effects are attributable to the enhanced 5-FU toxicity:
Very Common
Affects more than 1 in 10 patients
- Nausea
- Vomiting
- Severe diarrhea (can lead to dangerous dehydration)
- Dehydration (secondary to diarrhea)
- Mucositis — inflammation and ulceration of the mucous membranes in the mouth and gastrointestinal tract (life-threatening cases have occurred)
- Decreased blood cell counts (leukopenia, thrombocytopenia, potentially life-threatening)
Common
Affects up to 1 in 10 patients
- Hand-foot syndrome (palmar-plantar erythrodysesthesia) — redness, swelling, and peeling of the skin on the palms of the hands and soles of the feet
Frequency Not Known
Cannot be estimated from available data
- Elevated blood ammonia levels (hyperammonemia)
Contact your healthcare team or emergency services immediately if you experience any of the following: signs of a severe allergic reaction (swelling of lips, tongue, or throat; difficulty breathing; sudden rash; dizziness); severe or persistent diarrhea (more than 4 loose stools per day or any diarrhea with blood); fever or signs of infection (which may indicate critically low white blood cell counts); severe mouth sores making it difficult to eat or drink; or unusual bleeding or bruising.
It is important to report suspected side effects after a medication has been authorized. This helps to continuously monitor the benefit-risk balance of the medication. Healthcare professionals and patients are encouraged to report any suspected adverse reactions to their national pharmacovigilance authority (for example, the FDA MedWatch program in the United States or the Yellow Card Scheme in the United Kingdom).
How Should You Store Calciumfolinate Teva?
Proper storage of Calciumfolinate Teva is essential to maintain the medication's stability, sterility, and effectiveness. Although this medication is typically stored and managed by hospital pharmacies rather than by patients at home, understanding the storage requirements is important for healthcare professionals and for patient awareness.
The key storage requirements are as follows:
- Temperature: Store in a refrigerator at 2-8 degrees Celsius (36-46 degrees Fahrenheit). Do not freeze.
- Light protection: Store in the original carton to protect from light. Folinic acid is sensitive to light degradation, which can reduce the potency of the medication over time.
- Child safety: Keep out of the sight and reach of children at all times.
- Expiration date: Do not use after the expiration date stated on the carton after "EXP." The expiration date refers to the last day of the stated month.
- After dilution: Chemical and physical stability of the diluted solution has been demonstrated for up to 72 hours at room temperature (not exceeding 25 degrees Celsius). From a microbiological standpoint, the diluted product should be used immediately. If not used immediately, in-use storage times and conditions are the responsibility of the user and should not normally exceed 24 hours at 2-8 degrees Celsius, unless dilution has been performed under controlled and validated aseptic conditions.
Unused medication or pharmaceutical waste should be disposed of in accordance with local regulations for cytotoxic drug waste. Do not dispose of medications through household waste or wastewater. These measures help to protect the environment.
What Does Calciumfolinate Teva Contain?
Active Ingredient
The active substance is folinic acid, present at a concentration of 10 mg per ml in the form of its calcium salt (calcium folinate). Folinic acid is the international non-proprietary name (INN) for the 5-formyl derivative of tetrahydrofolic acid. In the United States, this substance is commonly referred to as leucovorin calcium. The two names — calcium folinate and leucovorin calcium — refer to the same active pharmaceutical ingredient and are used interchangeably in medical literature.
Inactive Ingredients (Excipients)
- Sodium chloride: Used to adjust the tonicity (osmolarity) of the solution to make it compatible with intravenous administration.
- Sodium hydroxide or hydrochloric acid: Used for pH adjustment to ensure the solution has a physiologically acceptable pH range.
- Water for injections: The solvent base of the formulation, meeting pharmacopoeial standards for sterile injectable preparations.
Physical Description and Pack Sizes
Calciumfolinate Teva is presented as a clear, yellowish solution, free from visible particles. It is supplied in glass vials in the following sizes: 5 ml, 10 ml, 20 ml, 30 ml, and 50 ml. Not all pack sizes may be marketed in every country. The solution is for single use only; any unused portion of the vial must be discarded after opening.
The product should be visually inspected before administration. If the solution appears cloudy, discolored, or contains particles, it must not be used and should be disposed of according to local pharmaceutical waste regulations.
Frequently Asked Questions
Calcium folinate (leucovorin) has two primary uses in cancer treatment. First, it serves as a "rescue" agent after high-dose methotrexate therapy. Methotrexate kills cancer cells by blocking folate metabolism, but it also damages normal cells. Calcium folinate provides normal cells with an active form of folate that bypasses the methotrexate block, protecting them from toxicity. Second, calcium folinate is combined with the chemotherapy drug 5-fluorouracil (5-FU) in the treatment of colorectal cancer and other solid tumors. In this setting, it enhances the anticancer effect of 5-FU by increasing the binding of the drug to its target enzyme, thymidylate synthase. This combination is the foundation of major chemotherapy regimens such as FOLFOX and FOLFIRI.
No, calcium folinate (folinic acid) is not the same as folic acid, although they are chemically related. Folic acid is the oxidized, inactive form of the vitamin that must be converted by the enzyme dihydrofolate reductase (DHFR) into its active tetrahydrofolate form before the body can use it. Folinic acid (calcium folinate) is already a reduced, biologically active form of the vitamin and does not require DHFR for activation. This distinction is critically important in medicine: when methotrexate blocks DHFR, folic acid cannot be activated and therefore cannot rescue cells from methotrexate toxicity. Folinic acid, however, bypasses this block entirely, making it the essential antidote in leucovorin rescue therapy.
Calciumfolinate Teva is administered by healthcare professionals in a hospital setting. It can be given by intravenous (IV) injection, intravenous infusion (drip), or intramuscular (IM) injection. For leucovorin rescue after methotrexate, it may be given as an IV bolus injection every 6 hours. For combination therapy with 5-fluorouracil, it is typically given as a 2-hour intravenous infusion. The solution can be diluted with 0.9% sodium chloride or 5% glucose for infusion. The IV injection rate must not exceed 160 mg per minute due to the calcium content. Since this is a hospital-administered medication, patients do not need to self-administer or manage their own doses.
Standard calcium folinate (leucovorin) is a racemic mixture, meaning it contains equal amounts of two mirror-image forms (isomers): the pharmacologically active L-isomer (levo form) and the inactive D-isomer (dextro form). Levofolinate (levoleucovorin) contains only the active L-isomer and is therefore given at half the dose of standard leucovorin. Both preparations are clinically equivalent when dosed appropriately — 200 mg/m² of leucovorin is equivalent to 100 mg/m² of levoleucovorin. Your oncologist may use either formulation depending on institutional protocols and availability.
Folic acid cannot be used as a methotrexate antidote because it requires the enzyme dihydrofolate reductase (DHFR) to be converted into its active form, and DHFR is precisely the enzyme that methotrexate inhibits. When methotrexate blocks DHFR, folic acid cannot be activated and remains pharmacologically useless. Folinic acid (calcium folinate), on the other hand, is already in a reduced, active form and enters the folate metabolic pathway downstream of the DHFR step. This allows it to provide cells with the active folate they need for DNA synthesis and survival, effectively rescuing them from methotrexate toxicity without requiring DHFR activity.
While calcium folinate can technically supply active folate to the body, it is not routinely used to treat simple folic acid deficiency because oral folic acid supplements are far less expensive, equally effective for this purpose, and much more convenient. Calcium folinate is a prescription injectable medication reserved for specific clinical scenarios in oncology. For routine folate deficiency or supplementation (such as during pregnancy), standard folic acid tablets are the appropriate treatment. However, calcium folinate should never be used to treat megaloblastic anemia caused by vitamin B12 deficiency, as it may mask the hematological signs of B12 deficiency while allowing potentially irreversible neurological damage to progress.
References
All medical information in this article is based on international guidelines, peer-reviewed research, and official regulatory documents. Evidence level: 1A (systematic reviews of randomized controlled trials).
- World Health Organization (WHO). WHO Model List of Essential Medicines — 23rd list (2023). Geneva: WHO; 2023. Calcium folinate listed as an essential antidote and cancer therapy adjunct.
- European Medicines Agency (EMA). Calcium Folinate Summary of Product Characteristics (SmPC). 2024. Comprehensive product information for healthcare professionals.
- U.S. Food and Drug Administration (FDA). Leucovorin Calcium Injection — Prescribing Information. 2023. FDA-approved labeling for leucovorin calcium injection.
- Cervantes A, Adam R, Rosello S, et al. Metastatic colorectal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Annals of Oncology. 2023;34(1):10-32. doi:10.1016/j.annonc.2022.10.003
- Advanced Colorectal Cancer Meta-Analysis Project. Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: evidence in terms of response rate. Journal of Clinical Oncology. 1992;10(6):896-903.
- Piedbois P, et al. Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: an updated meta-analysis. Journal of Clinical Oncology. 2004;22(18):3766-3775.
- British National Formulary (BNF). Folinic acid monograph. 2024. National Institute for Health and Care Excellence (NICE). Prescribing information and clinical guidance.
- Howard SC, McCormick J, Pui C-H, Buddington RK, Harvey RD. Preventing and Managing Toxicities of High-Dose Methotrexate. The Oncologist. 2016;21(12):1471-1482. doi:10.1634/theoncologist.2015-0164
Editorial Team
This article has been developed and reviewed by the iMedic Medical Editorial Team in accordance with our editorial standards. All medical claims are supported by peer-reviewed evidence from recognized international sources including the WHO, EMA, FDA, ESMO, and BNF.
iMedic Medical Editorial Team — Licensed specialists in clinical pharmacology and oncology with documented academic and clinical experience in cancer chemotherapy.
iMedic Medical Review Board — Independent panel of board-certified physicians who review all content according to the GRADE evidence framework and international clinical guidelines.
Conflict of Interest Declaration: The iMedic editorial team has no financial relationships with pharmaceutical companies. All content is independently produced with no commercial funding or sponsorship.